McEachron Kim 4
4 · GENOMIC HEALTH INC · Filed Aug 7, 2019
Insider Transaction Report
Form 4
McEachron Kim
Chief People Officer
Transactions
- Exercise/Conversion
Common Stock
2019-08-05$30.69/sh+9,665$296,619→ 46,137 total - Sale
Common Stock
2019-08-05$71.53/sh−12,103$865,723→ 36,472 total - Exercise/Conversion
Employee Stock Option (right to buy)
2019-08-05−9,665→ 0 totalExercise: $30.69Exp: 2022-03-12→ Common Stock (9,665 underlying) - Exercise/Conversion
Employee Stock Option (right to buy)
2019-08-05−2,438→ 6,562 totalExercise: $28.05Exp: 2023-01-31→ Common Stock (2,438 underlying) - Exercise/Conversion
Common Stock
2019-08-05$28.05/sh+2,438$68,386→ 48,575 total
Footnotes (6)
- [F1]Includes an aggregate of 11,261 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.
- [F2]These sales of common stock were effected pursuant to Rule 10b5-1 sales plan adopted by the reporting person on March 18, 2019.
- [F3]Reporting person undertakes to provide upon request by the Securities and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within the range indicated.
- [F4]Represents weighted average sale price. Actual sale prices ranged from $71.13 to $72.03.
- [F5]The option became exercisable as to 25% of the shares on March 12, 2013, and became exercisable as to 1/48th of the shares each full month thereafter.
- [F6]The option became exercisable as to 25% of the shares on January 31, 2014, and became exercisable as to 1/48th of the shares each full month thereafter.